PLANT-2 (EU & MHRA)

  • State-of-the-art facility with a built up area of 19230 Sq. meters
  • F & D Set-up equivalent to miniature production facility
  • HVAC and Water Purification Systems in line with CGMP standards
  • 100% Export Oriented Unit
  • UK MHRA & EU GMP Approved Site
  • Also approved for supplies to Australia, Canada and Ethiopia
  • Manufacturing Tablets and Capsules
  • Production Capacity – 3 billion tablets, 350 million capsules
  • 3 Granulation, 5 Compression, 4 Coating and 9 Packaging (including 1 Bulk Packaging line)
  • Manufacture of Site Transfer/Tech Transfer products for UK, EU, Australian and Canadian customers
  • Doing Product Development Projects for Regulated and Emerging Markets
  • Approved by Mylan and Aurobindo
  • USFDA Plant Approval is expected by Mar 2023

Reach Out for business requirements:

Mr. K.S. VASU
Chief Executive – Finance & Business Development

Email: vasu.ks@fourrts.com

Phone: +91 98401 38611